Company intelligence / Profile preview

Slayback Pharma

Princeton, New Jersey, United Statesazurity.com ↗

Ownership: Private
Employees: ~55
Development stage: Commercial

Overview

Slayback Pharma has developed a robust portfolio of complex generics with several commercialized products—especially in injectables—and late-stage assets. Notable launches include ready-to-use combination injectables like Prevduo™. The company’s acquisition by Azurity aims to accelerate the launch of new medicines targeting overlooked patient needs.

Therapeutic areas: OtherOphthalmologyNeurology
Modalities: Small molecules (complex generics, injectables, non-solid oral products)Combination products
Industry: Biotech

Partnerships

Dr. Reddy's Laboratories – licensing agreement for Brimonidine Tartrate Ophthalmic SolutionEndo – distribution partnership for Prevduo™ in the US

Beyond the preview

Go deeper on Slayback Pharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Slayback Pharma.

Explore the full profile